ArticleJournal of hematopathology2025
A rare case of primary testicular follicular lymphoma in a pediatric patient.
Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular follicular lymphoma (TFL) is an exceedingly rare lymphoma that typically occurs in young male patients and is now recognized as a distinct diagnostic entity in the International Consensus Classification. TFL shows some clinicopathologic and genetic overlap with pediatric-type follicular lymphoma (PTFL). We report a case of TFL occurring in an otherwise healthy 4-year-old boy who presented with painless scrotal swelling. Orchiectomy revealed a 1.5-cm left testicular mass. Histologic sections showed a dense lymphoid infiltrate with nodular/follicular architecture growing between the seminiferous tubules. The infiltrate was composed of CD20/PAX5-positive B-cells that coexpressed germinal center markers (CD10, BCL6, MEF2B); they were negative for BCL2. No BCL2 or BCL6 rearrangements and no TNFRSF14 deletion were detected by FISH. Chromosomal microarray analysis detected copy-neutral loss of heterozygosity (CN-LOH) at 1p36.33-p36.32 (region of TNFRSF14). Next-generation sequencing detected variants in GNA13, RHOA, and TNFRSF14. In conclusion, this case shows the classic clinical, pathologic, and genetic features of TFL and highlights the similarities to PTFL and the importance of distinguishing this entity from other subtypes of FL. Patients with TFL typically respond favorably to orchiectomy and chemotherapy and have excellent clinical outcomes.
Indexed as
Identifiers
39862366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.